Related Experiment Video
Updated: May 6, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
cMET as a potential therapeutic target in gastric cancer (Review)
1Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China.
Abstract:
Gastric cancer is one of the most common malignancies worldwide. Despite improvements in surgery and chemotherapy, the outcomes in patients with advanced gastric cancer remain poor. cMET is a member of the receptor tyrosine kinase family, and plays a key role in tumor survival, growth, angiogenesis and metastasis. cMET overexpression and/or gene amplification occurs in a significant proportion of gastric cancers. cMET is associated with a high tumor stage and poor prognosis. Several cMET inhibitors have been investigated in clinical trials, and the initial results are encouraging. It has become increasingly apparent that cMET is a promising therapeutic target in gastric cancer. In this review, we summarize the development of cMET inhibitors in the preclinical and clinical environment. In addition, we discuss the challenges of cMET-targeted therapy in gastric cancer and explore possible solutions.
Insights
Targeting cMET, a receptor tyrosine kinase, shows promise for advanced gastric cancer treatment. Inhibitors are under investigation, offering hope despite poor outcomes with current therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gastric cancer is a leading global malignancy with poor outcomes in advanced stages despite current treatments.
- cMET, a receptor tyrosine kinase, is crucial for tumor progression, including survival, growth, angiogenesis, and metastasis.
- Overexpression or amplification of cMET is frequent in gastric cancers, correlating with advanced stage and poor prognosis.
Purpose of the Study:
- To review the development of cMET inhibitors for gastric cancer.
- To discuss the therapeutic potential of targeting cMET in gastric cancer.
- To explore challenges and solutions for cMET-targeted therapy in gastric cancer.
Main Methods:
- Review of preclinical and clinical studies on cMET inhibitors in gastric cancer.
- Analysis of cMET's role in gastric cancer pathogenesis.
- Discussion of clinical trial data and therapeutic strategies.
Main Results:
- cMET plays a significant role in gastric cancer progression and is a targetable biomarker.
- Several cMET inhibitors have shown encouraging results in early clinical investigations.
- cMET inhibitors represent a promising therapeutic avenue for advanced gastric cancer.
Conclusions:
- cMET is a validated and promising therapeutic target for gastric cancer.
- Ongoing development of cMET inhibitors offers new hope for patients with advanced disease.
- Addressing challenges in cMET-targeted therapy is crucial for clinical success.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...